Literature DB >> 15617582

Dobutamine versus milrinone after subarachnoid hemorrhage.

Andrew Naidech1, Yunling Du, Kurt T Kreiter, Augusto Parra, Brian-Fred Fitzsimmons, Sean D Lavine, E Sander Connolly, Stephan A Mayer, Christopher Commichau.   

Abstract

OBJECTIVE: Neurogenic stunned myocardium is a well-recognized complication of subarachnoid hemorrhage. Dobutamine and milrinone are both used for neurogenic stunned myocardium, but there are few data comparing them after subarachnoid hemorrhage.
METHODS: We compared the physiological dose response of dobutamine and milrinone in patients with subarachnoid hemorrhage requiring a pulmonary artery catheter. We located 11 patients who received either inotrope. Physiological data were fitted to a mixed model accounting for drug, dose, and between-patient variation.
RESULTS: There were 11 patients who had 152 pulmonary artery catheter measurements. Two received both inotropes (but not within 4 h of each other), 2 only milrinone, and 7 only dobutamine. The groups had similar clinical and physiological characteristics. After adjustment for vasopressin, milrinone was significantly more potent in increasing cardiac output (P <0.0001) and stroke volume (P=0.03), while decreasing vascular resistance (P <0.0001) and systolic blood pressure (P=0.008), than dobutamine.
CONCLUSION: These data suggest that milrinone and dobutamine should be used in different clinical situations. Milrinone may be more effective in patients with severely depressed systolic function but who have at least normal vascular resistance and blood pressure and in whom raising cardiac output is the primary goal. Dobutamine may be superior when vascular resistance or blood pressure is low.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15617582     DOI: 10.1227/01.neu.0000144780.97392.d7

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  17 in total

1.  The importance of cardiac derangements after SAH.

Authors:  Andrew M Naidech
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 2.  Cardiovascular and pulmonary complications of aneurysmal subarachnoid hemorrhage.

Authors:  Nicolas Bruder; Alejandro Rabinstein
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 3.  Neurogenic Stunned Myocardium in Severe Neurological Injury.

Authors:  Benjamin B Kenigsberg; Christopher F Barnett; Jeffrey C Mai; Jason J Chang
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

Review 4.  Autonomic dysfunction syndromes after acute brain injury.

Authors:  Courtney Takahashi; Holly E Hinson; Ian J Baguley
Journal:  Handb Clin Neurol       Date:  2015

5.  Continuous cardiac output and near-infrared spectroscopy monitoring to assist in management of symptomatic cerebral vasospasm after subarachnoid hemorrhage.

Authors:  Tatsushi Mutoh; Tatsuya Ishikawa; Akifumi Suzuki; Nobuyuki Yasui
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

Review 6.  Rescue therapy for refractory vasospasm after subarachnoid hemorrhage.

Authors:  Julia C Durrant; Holly E Hinson
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

7.  Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage.

Authors:  Sirisha Yarlagadda; Pam Rajendran; Jacob C Miss; Nader M Banki; Alexander Kopelnik; Alan H B Wu; Nerissa Ko; Adrian W Gelb; Michael T Lawton; Wade S Smith; William L Young; Jonathan G Zaroff
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 8.  Neurogenic stunned myocardium.

Authors:  Hoang Nguyen; Jonathan G Zaroff
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

Review 9.  Management of aneurysmal subarachnoid hemorrhage.

Authors:  Michael N Diringer
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

Review 10.  Advanced monitoring of systemic hemodynamics in critically ill patients with acute brain injury.

Authors:  Fabio Silvio Taccone; Giuseppe Citerio
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.